SGYP Profile
Synergy Pharmaceuticals, Inc. (SGYP) is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal (GI) disorders. The company's lead product, Trulance, is approved for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation in adults.
Trulance is a once-daily tablet that acts as a guanylate cyclase-C agonist to stimulate intestinal fluid secretion, increase transit, and improve bowel movements. Synergy is also exploring Trulance's potential for use in other GI conditions, including opioid-induced constipation and ulcerative colitis.
In addition to Trulance, Synergy has a pipeline of other GI-focused product candidates, including dolcanatide, which is being developed for the treatment of ulcerative colitis, and SP-333, which is being developed for the treatment of opioid-induced constipation.
Synergy has partnerships with several major pharmaceutical companies, inclding Mitsubishi Tanabe Pharma Corporation, which is helping to develop and commercialize Trulance in Japan.
As of September 2019, Synergy had a market capitalization of approximately $130 million.
|
